| Autor: |
James G. Christensen, Pasi A. Jänne, Mark M. Awad, Nir Peled, Geoffrey I. Shapiro, Mizuki Nishino, Carrie Graveel, Sandip Pravin Patel, Lyudmilla Bazhenova, Peter Olson, Richard B. Lanman, Darya I. Chudova, Richard Chao, Vanessa Tassell, Manuel Hidalgo, Camino Menendez, Natalia Baños, Pedro P. Lopez-Casas, Jill Hallin, David Briere, Harrah Chiang, Zachary Madaj, Curt J. Essenburg, Elizabeth A. Tovar, Matthew Lee, Ruth Aranda, Lars D. Engstrom |
| Rok vydání: |
2023 |
| Popis: |
Supplemental Figure 1. Glesatinib is a potent and selective MET inhibitor. Supplemental Figure 2. Waterfall plot of glesatinib activity across pre-clinical tumor models. Supplemental Figure 3. SNU-638 Criz-res line is homogeneous and harbors the F1200L and Y1230H resistance mutations on the same allele. Supplemental Figure 4. Long term treatment of a METex14 del mutant and amplified PDX model (PULM-039) leads to capmatinib and crizotinib-resistant tumors but not glesatinib-resistant tumors. Supplemental Figure 5. Molecular basis for resistance that arises from the G1163R mutation. Supplemental Figure 6. Glesatinib is active against type I MET inhibitor-resistance mutations in a spheroid growth assay. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
